For Non-Small Cell Lung Cancer, Bevacizumab Plus Chemotherapy Not Effective
Bevacizumab, paclitaxel, and carboplatin did not achieve the prespecified objective response rate goal for non-small cell lung cancer.
Diagnosis & Disease Information
XALKORI® (crizotinib) for Locally Advanced or Metastatic ALK+ NSCLC
This slideshow reviews drug information for XALKORI® (crizotinib), indicated for locally advanced or metastatic ALK+NSCLC. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 8: Use in Specific PopulationsSlide 10: Clinical PharmacologySlide 15: Warnings and PrecautionsSlide 19: Clinical Safety and EfficacySlide 27: Drug Storage and Supply Slide 29: References
For Non-Small Cell Lung Cancer, Nintedanib Improves Overall Survival Without Reducing Quality of Life
Nintedanib plus docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC) improves overall survival without decreasing quality of life.
Cyramza Gains New Indication for Metastatic Lung Cancer (NSCLC)
The FDA has expanded the indication of Cyramza (ramucirumab) for the treatment of metastatic non-small cell lung cancer (NSCLC).
Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
[Lung Cancer: Targets and Therapy] The appropriate role of EGFR mutation analysis in the treatment of patients with NSCLC is constantly evolving; EGFR mutation testing can help simplify the drug discovery process and individualize cancer therapy.
In Stage 3 NSCLC, Cisplatin Plus Etoposide vs. Carboplatin Plus Paclitaxel Show Similar Survival
Etoposide plus cisplatin results in a similar overall survival as carboplatin plus paclitaxel for non-small cell lung cancer (NSCLC).
Rociletinib May Be Safe, Effective for the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
Rociletinib may be effective in treating patients with advanced EGFR-mutated NSCLC with or without the T790M mutation.
Figitumumab Not Safe or Effective for Advanced Non-Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC)
Figitumumab to erlotinib did not improve overall survival in patients with advanced, non-adenocarcinoma non-small cell lung cancer (NSCLC).
Nivolumab May Be Effective For Patients With Non-Small Cell Lung Cancer
Stufy of the efficacy and safety of nivolumab in patients with squamous non-small cell lung cancer (NSCLC).
PORT Can Improve Survival for Non-Small Cell Lung Cancer (NSCLC) Patients
Patients who underwent post-operative radiation therapy (PORT) for non-small cell lung cancer (NSCLC) survived 4 months longer.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...